Biogen falls on analysts' downgrades

Merrill Lynch analyst Eric Hecht and Lehman Brothers analyst Rachel Leheny both downgraded BGEN to a long-term neutral and a market perform, respectively, based on the results from Serono's Rebif- Avo...